VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Coya Therapeutics, Inc. Executive Compensation (FY25)

COYA · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Arun Swaminathan
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Coya Therapeutics, Inc. brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 27, 2026Latest filing (DEF 14A): May 13, 2026
3 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Coya Therapeutics, Inc. brief$1,500Get the executive brief
Velarion Intel, one year, every company
125 figures on this page, cited to the filing that reported them. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Arun Swaminathan: $1,497,168 → $2,091,007 (39.7% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Coya Therapeutics, Inc.'s chief executive and what were they paid?
Arun Swaminathan was paid $2,091,007 in total compensation as Chief Executive Officer, Director for fiscal 2025. Compared with the $1,497,168 reported for fiscal 2024, Swaminathan's total was 39.7% higher.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Adrian Hepner
Former President, Chief Medical Officer
◇◇—◇———◇
David Snyder
Chief Financial Officer and Chief Operating Officer
◇◇—◇———◇
Howard Berman
Chief Executive Officer
◇◇—————◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Howard Berman
Chief Executive Officer
◇◇—◇———◇
David Snyder
Chief Financial Officer and Chief Operating Officer
◇◇—◇———◇
Adrian Hepner
Former President, Chief Medical Officer
Departed during or after this year
◇——◇———◇
Fred Grossman
President, Chief Medical Officer
◇◇—◇———◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Howard Berman
Former Chief Executive Officer, Former Executive Chairman of the Board
◇◇—◇———◇
Fred Grossman
President, Chief Medical Officer
◇◇—◇———◇
Arun Swaminathan
Chief Executive Officer, Director
◇◇—◇———◇
David Snyder
Chief Financial Officer and Chief Operating Officer
◇◇—◇———◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Arun Swaminathan
Chief Executive Officer, Director
◇◇—◇———◇
Howard Berman
Former Chief Executive Officer, Former Executive Chairman of the Board
Departed during or after this year
◇◇—◇———◇
Fred Grossman
President, Chief Medical Officer
◇◇—◇———◇
David Snyder
Chief Financial Officer and Chief Operating Officer
◇◇—◇———◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2023
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Fred GrossmanOPTION◇——◇—◇◇
Howard BermanOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Arun SwaminathanOption◇—◇1/8/2035
Option◇—◇5/23/2034
Option◇—◇1/31/2034
Option◇—◇4/3/2033
Howard BermanOption◇—◇1/8/2035
Option◇—◇5/23/2034
Option◇—◇1/31/2034
Option◇—◇2/27/2033
Fred GrossmanOption◇—◇1/8/2035
Option◇—◇5/23/2034
Option◇—◇1/31/2034
Option◇—◇7/17/2033
Option◇—◇1/31/2034
David SnyderOption◇—◇1/8/2035
Option◇—◇5/23/2034
Option◇—◇1/31/2034
Option◇—◇2/27/2033
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Dov Goldstein
◇—◇———◇
Anabella Villalobos
◇—◇———◇
Dieter Weinand
◇—◇———◇
Ann Lee
◇—◇———◇
Wilbur Ross
◇—◇———◇
Mark Pavao and Arun Swaminathan served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Arun Swaminathan (Chief Executive Officer, Director), FY2025 total compensation $2,091,007 (base salary $546,000) [exec_comp, SEC accession 0001193125-26-220688, filed 2026-05-13]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Coya Therapeutics, Inc. files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Coya Therapeutics, Inc. disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Coya Therapeutics, Inc.'s disclosed peer group is defensible, who names Coya Therapeutics, Inc. back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
125 figures on this page, cited to the filing that reported them.
125 cited to the filing

Documents cited

  1. 0001193125-26-220688
    DIRECTOR COMPENSATION · Outstanding Equity Awards at Fiscal Year End · Summary Compensation Table
  2. 0000950170-24-038090
    Summary Compensation Table
  3. 0001193125-23-149377
    Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Coya Therapeutics, Inc. executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/COYA (accessed 2026).
Short form: data: Velarion

The Coya Therapeutics, Inc. brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Coya Therapeutics, Inc. and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy